Compare ILMN & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ILMN | RMD |
|---|---|---|
| Founded | 1998 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.0B | 33.6B |
| IPO Year | 2000 | 1996 |
| Metric | ILMN | RMD |
|---|---|---|
| Price | $202.21 | $239.10 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 20 |
| Target Price | $261.45 | ★ $264.33 |
| AVG Volume (30 Days) | ★ 2.1M | 1.3M |
| Earning Date | 10-29-2026 | 10-29-2026 |
| Dividend Yield | N/A | ★ 1.11% |
| EPS Growth | ★ 170.87 | 9.67 |
| EPS | ★ 3.65 | 2.92 |
| Revenue | ★ $4,343,000,000.00 | $2,957,013,000.00 |
| Revenue This Year | $6.61 | $3.12 |
| Revenue Next Year | $7.00 | $6.43 |
| P/E Ratio | ★ $54.19 | $81.62 |
| Revenue Growth | N/A | ★ 13.44 |
| 52 Week Low | $112.65 | $180.27 |
| 52 Week High | $309.35 | $277.67 |
| Indicator | ILMN | RMD |
|---|---|---|
| Relative Strength Index (RSI) | 33.96 | 51.20 |
| Support Level | $200.01 | $218.45 |
| Resistance Level | $201.83 | $257.89 |
| Average True Range (ATR) | 12.45 | 7.67 |
| MACD | -4.42 | -0.69 |
| Stochastic Oscillator | 4.20 | 51.62 |
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea, combined with aging populations and increasing prevalence of obesity, is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.